Loading…
Aspen Aesthetics dba Fifty 410 was cited for misbranding compounded semaglutide and tirzepatide products sold through their website. The company falsely represented that Fifty 410 was the compounder of these drugs when it was not, and made unsupported claims that the products contained "clinically proven ingredients," implying FDA approval or safety evaluation that had not occurred. These violations of sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act resulted in misbranded drugs being introduced into interstate commerce without proper authorization or substantiation.